Keros Therapeutics to Speak at 29th European Hematology Congress

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts, is set to present five abstracts from its KER-050 (elritercept) program at the 29th Annual Congress of the European Hematology Association (EHA). This event will take place both virtually and in person from June 13 to 16, 2024. The abstracts were posted on the EHA website on May 14, 2024.

The first clinical presentation, titled "Durable clinical treatment with elritercept (KER-050) treatment: Findings from an ongoing Phase 2 trial in participants with lower-risk MDS," will be featured on June 14, 2024, from 8:45 a.m. to 10:00 a.m. Eastern time. This presentation falls under the session titled "Immune and targeted therapies in MDS" and will highlight the sustained treatment benefits of KER-050 for patients with lower-risk myelodysplastic syndromes (MDS).

The second clinical presentation is titled "Activin A Inhibition by elritercept (KER-050) is associated with evidence of cardiovascular benefit: Translation of preclinical observations to humans with MDS." It will be part of a poster session on June 14, 2024, from 12:00 p.m. to 1:00 p.m. Eastern time. This research demonstrates cardiovascular benefits in MDS patients treated with KER-050.

Another significant clinical presentation, "Elritercept (KER-050) demonstrated potential to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias in the Phase 2 RESTORE Trial," is scheduled for June 15, 2024, from 5:30 a.m. to 6:45 a.m. Eastern time. This presentation will be a part of the session "Clinical advances in myelofibrosis and mastocytosis," shedding light on KER-050’s potential in treating myelofibrosis and reducing the side effects related to ruxolitinib therapy.

On June 15, 2024, from 8:45 a.m. to 10:00 a.m. Eastern time, Keros will present "Reduced ferritin and increased bone-specific alkaline phosphatase in participants with lower-risk MDS treated with elritercept (KER-050) support potential to rebalance the osteohematopoietic niche." This presentation is part of the session "Iron metabolism: From basics to the clinic." It explores how KER-050 can influence ferritin levels and bone health in MDS patients.

Additionally, a preclinical presentation titled "RKER-050, a modified activin receptor type IIA ligand trap, rescued anemia and increased muscle mass and strength in a mouse model of myelofibrosis" will be featured on June 14, 2024, from 12:00 p.m. to 1:00 p.m. Eastern time during a poster session. This study underscores the efficacy of KER-050 in improving anemia and muscle parameters in preclinical settings.

Keros Therapeutics is dedicated to developing innovative therapeutics to address disorders stemming from dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. Their leading product candidate, KER-050, is an engineered ligand trap targeting activin receptor type IIA, aimed at treating cytopenias such as anemia and thrombocytopenia in patients with MDS and myelofibrosis. Keros' strategic focus lies in translating their deep understanding of TGF-ß signaling into meaningful clinical benefits.

Apart from KER-050, Keros is advancing other promising therapeutics. Their second candidate, KER-012 (cibotercept), is being developed for pulmonary arterial hypertension and cardiovascular disorders. Another product, KER-065, targets obesity and neuromuscular diseases.

Keros continues to be a frontrunner in the field by leveraging its insights into the TGF-ß protein family, potentially offering disease-modifying treatments that can substantially improve patient outcomes across various medical conditions.